Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

License, Clinical Trial and Sponsored Research Agreements (Tables)

License, Clinical Trial and Sponsored Research Agreements (Tables)

6 Months Ended

Jun. 30, 2021

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Schedule of License, Clinical Trial and Sponsored Research Agreements

For the three and six months ended June 30, 2021 and 2020, the Company recorded the following expense in research and development for licenses acquired:


	For the three months ended June 30,				For the six months ended June 30,
($ in thousands)	2021		2020		2021		2020
City of Hope National Medical Center
CD123	$	250	$	334	$	250	$	334
IL13Rα2		—		333		—		333
Spacer		—		333		—		333
HER2		—		—		—		250
Fred Hutchinson Cancer Research Center - CD20		—		300		—		300
Mayo Clinic		750		—		750		—
Total	$	1,000	$	1,300	$	1,000	$	1,550

Sponsored Research and Clinical Trial Agreements [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Schedule of License, Clinical Trial and Sponsored Research Agreements

For the three and six months ended June 30, 2021 and 2020, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:


	For the three months ended June 30,				For the six months ended June 30,
($ in thousands)	2021		2020		2021		2020
City of Hope National Medical Center	$	—	$	—	$	—	$	500
CD123		21		65		226		296
IL13Rα2		279		234		793		326
CS1		197		770		372		770
HER2		31		—		154		—
PSCA		(4)		—		46		—
Fred Hutchinson Cancer Research Center - CD20		327		189		998		716
St. Jude Children's Research Hospital - XSCID		176		1,558		280		1,558
Mayo Clinic		233		—		233		—
Total	$	1,260	$	2,816	$	3,102	$	4,166